INOVIO to Develop DNA-encoded Monoclonal Antibody (dMAb ®) Candidates to Treat COVID-19 with Funding from the Defense Advanced Research Projects Agency (DARPA) and the Department of Defense's (DoD) Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND)
PLYMOUTH MEETING, Pa., Dec. 15, 2020 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases and cancer, today announced... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - December 15, 2020 Category: Pharmaceuticals Source Type: clinical trials
Rationale and design of repeated cross-sectional studies to evaluate the reporting quality of trial protocols: the Adherence to SPIrit REcommendations (ASPIRE) study and associated projects
DiscussionThe ASPIRE study and associated substudies will provide important information on the impact of measures to improve the reporting of RCT protocols and on multiple aspects of RCT design, trial registration, premature discontinuation, and non-publication of RCTs observing potential changes over time. (Source: Trials)
Source: Trials - October 28, 2020 Category: Research Source Type: clinical trials
Letter on Predicting the number of sites needed to deliver a multicentre clinical trial within a limited time frame in the UK
AbstractWhen planning a multicentre clinical trial, it can be difficult to predict the time needed to open individual sites, and this in turn impacts on the total number of sites needed, the budget and the time frame for a clinical trial to be delivered successfully. This is of particular importance for funding applications with a limited time frame and budget such as NIHR RfPB. It is more efficient and cost-effective to open the total number of sites needed at the outset of a trial, rather than to respond later to slow site opening and recruitment. Here, we share our experience of successfully delivering a multicentre cli...
Source: Trials - October 21, 2020 Category: Research Source Type: clinical trials
BioNTech to Receive up to €375M in Funding from German Federal Ministry of Education and Research to Support COVID-19 Vaccine Program BNT162
MAINZ, GERMANY, September 15, 2020 — BioNTech SE (Nasdaq: BNTX,“BioNTech” or“the Company”) today announced that it will receive a grant of up to 375 million Euro from an initiative by the German Federal... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - September 15, 2020 Category: Pharmaceuticals Source Type: clinical trials
A quadruple blind, randomised controlled trial of gargling agents in reducing intraoral viral load among hospitalised COVID-19 patients: A structured summary of a study protocol for a randomised controlled trial
This study protocol was registered atwww.clinicaltrials.gov on 10 April 2020NCT04341688.Full protocolThe full protocol is attached as an additional file, accessible from the Trials website (Additional file1). In the interest in expediting dissemination of this material, the familiar formatting has been eliminated; this Letter serves as a summary of the key elements of the full protocol. The study protocol has been reported in accordance with the Standard Protocol Items: Recommendations for Clinical Interventional Trials (SPIRIT) guidelines (Additional file2).Fig. 1Flow diagram of study-participants ’ timeline (Source: Trials)
Source: Trials - September 13, 2020 Category: Research Source Type: clinical trials
Novavax Announces $1.6 Billion Funding from Operation Warp Speed
GAITHERSBURG, Md., July 07, 2020 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq: NVAX), a late stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced that it has been selected... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - July 7, 2020 Category: Pharmaceuticals Source Type: clinical trials
Eurythmy therapy versus slow movement fitness in the treatment of fatigue in metastatic breast cancer patients: study protocol for a randomized controlled trial
This study is the first-known randomized clinical trial assessing eurythmy therapy in the treatment of fatigue in metastatic breast cancer patients. Given the distress that fatigue causes patients, it is important to validate treatment options. If eurythmy therapy proves beneficial in CRF as part of this randomized controlled clinical trial, the study may be very impactful with implications not only for metastatic breast cancer patients but also for other cancer patients, health care personnel, scientists, and funding and regulatory bodies.Trial registrationThe ERYT/CoordiFit trial was registered at the US National Institu...
Source: Trials - July 5, 2020 Category: Research Source Type: clinical trials
The Safety & Efficacy of Imatinib for the Treatment of SARS-COV-2 Induced Pneumonia
Condition: COVID-19 Interventions: Drug: Imatinib Mesylate; Drug: Standard of Care Sponsors: Alexandria University; Science, Technology& Innovation Funding Authority (STIFA), Egypt Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 9, 2020 Category: Research Source Type: clinical trials
